We’ve joined the American Cancer Society in the fight to end cancer, forging an innovative partnership you can support.
Global Perspectives: Can momentum in small caps continue?
The factors driving momentum in small-cap equities and our view on what’s ahead.
Greenwood Project interns offer insights for financial industry professionals
This year’s Greenwood Project interns offered insights into how young Americans view the financial industry and their own financial futures.
Henderson High Income Trust plc: Half-Year Results 2024
Fund Manager, David Smith, discusses the half-year results for Henderson High Income Trust plc (HHI) and the outlook for the UK market.
Credit markets: tough to love, tough to hate
Corporate bond valuations are rich but arguably justified by strong credit fundamentals.
Seeking to capitalize on insurance’s extended cycle
The factors driving an extended insurance pricing cycle in the U.S. and how to navigate the growth opportunities and risks present in this evolving landscape.
Global Small Cap – strategy update
Nick Sheridan, Portfolio Manager on the European Equities team, on Tuesday 24 September delivered a quarterly update on the Global Small Cap strategy, as well as sharing the latest market perspectives and outlook.
The growing role of Asia for income – Henderson Far East Income Limited
Henderson Far East Income Limited aims to benefit from Asia’s rising dividends. This infographic explains why and how Asia’s income has grown.
Tim Walbert
Tim Walbert is currently senior advisor, Amgen. Most recently, Mr. Walbert served as the chairman, president and chief executive officer of Horizon Therapeutics from 2008 to October 2023, when it was acquired by Amgen for $28.3 billion. Before joining Horizon, he was president, chief executive officer and director of IDM Pharma Inc., a public biotechnology
Chris Ronan, CFA
